Physiotherapy Treatment in Women With Dyspareunia Following Gynecological Cancer: a Pilot Study
Study Details
Study Description
Brief Summary
Gynecological cancers represent more than half of female cancers. It has been clearly established that cancer survivors suffer from important health issues such as pain during sexual intercourse (dyspareunia) and sexual dysfunctions which sorely impact their quality of life. Although it affects more than 63% of cancer survivors, the available treatments remain limited and poorly studied. Cancer survivors are thus confronted with these health issues as well as relationship difficulties and psychological consequences, with limited treatment avenues. Addressing pelvic floor muscle dysfunctions and loss of vaginal elasticity, pelvic floor physiotherapy was shown to be effective in reducing or even alleviating dyspareunia and improving sexual function. Until now, no study investigated this treatment in gynecological cancer survivors with dyspareunia. Therefore, there is a need to examine pelvic floor physiotherapy to determine whether or not gynecological cancer survivors with dyspareunia could benefit from this treatment. The objectives of this single-arm mixed-method study are to evaluate the acceptability and feasibility of a physiotherapy treatment in gynecological cancer survivors suffering from dyspareunia and to explore treatment effects. This single-arm study using mixed methods will involve three data collections (pre- and post-treatment assessments). These assessments will be carried out by physiotherapists. Participants will receive physiotherapy treatment weekly in individual 60-minute sessions for 12 weeks. Thirty-one gynecological cancer survivors with vulvovaginal pain during sexual intercourse for at least 3 months will be recruited. The results of this study will bring new information regarding physiotherapy treatment for this population in preparation for a definitive randomized controlled trial.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Physiotherapy 12 weekly 60-minute individual sessions of multimodal physiotherapy including education, stretching techniques, pelvic floor muscle biofeedback as well as home exercises. |
Other: Physiotherapy
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Adherence rates [Pre- to 2-week post-treatment assessment]
To determine acceptability.
- Retention rate [Pre- to 2-week post-treatment assessment]
To determine feasibility.
Secondary Outcome Measures
- Change from baseline in pain [Pre- to 2-week post-treatment assessment]
To explore changes in pain during sexual intercourse (Numerical Rating Scale, ranging from 0 to 10, where 0 is no pain at all, and 10 is the worst pain ever).
- Change from baseline in sexual function [Pre- to 2-week post-treatment assessment]
To explore changes in sexual function (Female Sexual Function Index).
- Change from baseline in pelvic floor muscle function [Pre- to 2-week post-treatment assessment]
To explore changes in pelvic floor muscle function at rest and during contraction (dynamometry and ultrasound).
- Change from baseline in quality of life [Pre- to 2-week post-treatment assessment]
To explore changes in quality of life (questionnaire).
- Patient's global impression of change [2-week post-treatment assessment]
To determine patient self-reported improvement (Patient's Global Impression of Change).
- Adverse events [Pre- to 2-week post-treatment assessment]
To document any adverse events.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
History of gynecological cancer (endometrial, cervical, vaginal or other parts of the uterus)
-
Scheduled oncological treatments completed with no signs of cancer for at least 3 months
-
Vulvovaginal pain during sexual intercourse for at least 3 months
Exclusion Criteria:
-
Vulvovaginal pain before cancer and not related to sexual intercourse
-
Medication recognized to affect pain
-
Refuse to stop other treatments until post-treatment assessment
-
Other conditions interfering with assessment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke | Sherbrooke | Quebec | Canada | J1H 5N4 |
Sponsors and Collaborators
- Université de Sherbrooke
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- Institut Universitaire de Gériatrie de Montréal
- Jewish General Hospital
- Centre hospitalier de l'Université de Montréal (CHUM)
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MP-31-2016-1322